Brookfield Corp’s BridgeBio Pharma BBIO Stock Holding History

Brookfield Corp’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,193	Closed	-$381K	–	545
2021 Q1	$381K	Buy	+6,193	New	+$405K	﹤0.01%	430

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

AIG

American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brookfield Corp's BBIO Position: Q2 2021 in Review

Brookfield Corp sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 6,193 shares — an estimated $381K sold.

Brookfield Corp first reported a position in BBIO in Q1 2021 and held it in 1 quarter. The position peaked at $381K in Q1 2021. 201 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Brookfield Corp reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
Brookfield Corp sold 6,193 BridgeBio Pharma shares in Q2 2021, an estimated $381K.
Brookfield Corp first reported a position in BridgeBio Pharma in Q1 2021 and held it in 1 quarter.
Brookfield Corp's BridgeBio Pharma position peaked at $381K in Q1 2021.
201 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Brookfield Corp's 13F filing for Q2 2021, filed 17 Aug 2021.